Angelique Richardson, MD, PhD Awarded Funding Through Merck Investigator Studies Program |
Moores Member Dr. Angelique Richardson, a breast medical oncologist who studies breast cancer disparities and a second-year Robert A Winn Diversity in Clinical Trials Program Scholar, has secured funding through the Merck Investigator Studies Program to support her investigator-initiated trial, "Development and Implementation of an Academic-Community Partnership to Address the Breast Cancer Survival Disparity Among Black Women in San Diego by Increasing Enrollment in Clinical Trials," which will address modifiable factors that affect Black breast cancer patient enrollment in clinical trials.
|
|
|
NIH Awards Coast-To-Coast (C2C) Consortium $5.6 Million for All of Us Research Program |
Researchers at UC San Diego have been awarded a $5.6 million C2C grant to further their pioneering efforts through the NIH All of Us Research Program, which facilitates participant engagement, enrollment, data collection, and retention.
|
Machine Learning for Personalized Cancer Care: Director’s Seminar Series |
On June 5, 2024 at 12:00 p.m., Adam Yala, PhD will present “Machine Learning for Personalized Cancer Care” for this session of the Distinguished Scientist Director's Seminar Series.
|
Funding Opportunities Available on the Moores Website |
The Moores grants and funding webpage has been upgraded. Visit the link below to learn details about federal, non-federal, and limited submission funding opportunities available to Moores Members and researchers.
|
|
|
June 3, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
Cancer Control Work in Progress (WIP) Series |
May 15, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons
|
June 5, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
June 12, 2024 | 12:00 p.m. to 1:00 p.m.
Leichtag Biomedical Research Building, Room 107 and Zoom
|
June 14, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
|
|
Moores Speed Mentoring Workshop |
Thursday, June 13, 2023 | 1:00 p.m. to 2:00 p.m.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Pre-Award Services and How to Access—the following services are provided for Moores Members and/or grant proposals to take place in Moores: |
-
Uploading proposal documents to internal and external submission systems
- Providing review of the application for completion
- Preparing budgets and budget justifications
- Facilitating adherence to checklists and timelines
- Serving as liaison between PI and OCGA/HSSPPO
-
Providing assistance with JIT (just-In-time) requests
|
Grant Development Services and How to Access—the following services are provided for all Moores Members, based on priority: |
-
Reserving or requesting services
- Identifying funding opportunities
- Providing templates and examples
- Providing scientific review and/or meticulous editing for clarity, consistency, and persuasion
- Crafting supporting documents (e.g., Letters of Support; Facilities; Biosketch formatting/editing; wording sections for lay audiences)
|
Pre-Award and Grant Development Services Slide Deck (will insert, already uploaded to MyEmma)
|
|
|
| Geographic variation of mutagenic exposures in kidney cancer genomes |
Erik N. Bergstrom, PhD (Structural and Functional Genomics) and Ludmil Alexandrov, PhD (Structural and Functional Genomics)
|
|
|
| Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes |
Rana McKay, MD (Solid Tumor Therapeutics)
|
|
|
|
A Randomized trial of two remote healthcare delivery models on the uptake of genetic testing and impact on patient-reported psychological outcomes in families with pancreatic cancer: The Genetic Education, Risk Assessment, and testing (GENERATE) study |
Andrew Lowy, MD (Solid Tumor Therapeutics), Lisa Madlensky, PhD (Cancer Control Program), and Scott Lippman, MD (Cancer Control Program)
|
| |
CLINICAL TRIALS OFFICE (CTO) |
KO-MEN-007: Phase I Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib or Standard Induction Cytarabine/Daunorubicin (73) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia |
PI: James Mangan, MD, PhD
NCT: NCT06001788
|
SGNTV-001: Open Label Phase II Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors |
PI: Assuntina Sacco, MD
NCT: NCT03485209
|
JCAR017-EAP-001: Expanded Access Protocol (EAP) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (OOS) for Commercial Release |
PI: Dimitrios Tzachanis, MD, PhD
NCT: NCT04400591
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT (COE) |
Indian Health Council Annual Gathering at the Pala Reservation |
This past Saturday, COE attended the health gathering annually hosted by the Indian Health Council on the Pala reservation. COE interacted with over 50 community members and shared cancer prevention information and resources.
|
Inaugural Clinical Trials Patient Appreciation Day
|
COE was proud to support Clinical Trials Office colleagues for the inaugural Clinical Trials Patient Appreciation Day. COE looks forward to embracing patient stories and enhancing access to clinical trials for everyone in the Moores catchment area.
|
U.S. - Mexican Consulate Health Fair |
COE liaisons, Dahlia and Krzel, represented Moores at this month's health fair held at the U.S.-Mexican Consulate, where they shared Spanish-language cancer prevention materials and connected with community partners.
|
|
|
|
